<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709082</url>
  </required_header>
  <id_info>
    <org_study_id>2017-IIT-HER2-Aspire</org_study_id>
    <nct_id>NCT03709082</nct_id>
  </id_info>
  <brief_title>Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I/II Study of Palbociclib, Letrozole and T-DM1 in Trastuzumab Refractory Estrogen Receptor Positive (ER+) and HER2 Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the recommend dose of palbociclib in combination with letrozole and
      another medication, Ado-trastuzumab emtansine (T-DM1). Additionally, researchers will
      determine how well this recommended dose will improve outcomes in this type of advanced
      breast cancer.

      The study will include a safety lead-in with escalating dosing of palbociclib to determine
      the recommended phase II dose (RP2D) of palbociclib in this combination and an expanded phase
      II of palbociclib at the RP2D in combination with letrozole and Ado- trastuzumab Emtansine
      (T-DM1).

      The starting dose of palbociclib will be 75 milligrams (mg) by mouth (PO) daily for each 21
      day cycle. If 0 of 3 patients at the 75mg dose level experience a dose limiting toxicity
      (DLT), the next 3 patients will be enrolled at the next higher dosing cohort of 100mg PO
      daily for each 21 day cycle. If 0 of 3 patients at the 100mg dose level experience a DLT, the
      next 3 patients will be enrolled at the next higher dosing cohort of 125mg PO daily for each
      21 day cycle. If 0 of 3 patients at the 125mg dose level experience a DLT, 125mg PO daily of
      palbociclib will be the phase II recommended dose used in the phase II expanded cohort.
      Patients receiving the phase II recommended dose in phase I will be enrolled in phase II of
      the study.

      During safety lead-in and expanded phase II, Letrozole 2.5mg PO will be administered daily
      for each 21 day cycle and T-DM1 3.6 milligrams per kilograms intravenously (IV) will be
      administered on Day 1 of each 21 day cycle.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Anticipated">October 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Overall Response</measure>
    <time_frame>From the time of first documented complete response or appearance of one or more new lesions, until the first documented date of recurrent or progressive disease, whichever came first, assessed up to 5 years</time_frame>
    <description>Determine overall response rate (ORR), defined per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with complete response (CR).</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Defined per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with partial response (PR).</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Defined per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with stable disease (SD).</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Defined per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with Grade 3 or higher adverse event.</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Defined per Common Terminology Criteria for Adverse Events (CTCAE) v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Determine safety and tolerability of the intervention, defined per Common Terminology Criteria for Adverse Events (CTCAE) v4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a worsening Patient Reported Outcomes of Adverse Events (PRO-AE) score</measure>
    <time_frame>At baseline and Day 1 of each cycle, up to 5 years (each cyle is 21 days)</time_frame>
    <description>PRO-AE score defined per Patient Reported Outcome Measurement Information System (PROMIS) and Breast Cancer Prevention Trial (BCPT) Symptom Checklist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak observed plasma concentration</measure>
    <time_frame>Cycle 1, Day 1: 0 ,2,4 and 8 hours post treatment; Cycle 1, Day 15: 0 hours post treatment (each cyle is 21 days)</time_frame>
    <description>Defined per maximum observed concentration (Cmax) and time of Cmax (Tmax).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>Breast Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Phase 1: Palbociclib 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palbociclib 75 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Palbociclib 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palbociclib 100 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Palbociclib 125 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palbociclib 125 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: RP2D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recommended Phase 2 dose (RP2D; determined during Phase 1 Safety Run In) Palbociclib by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib 75mg</intervention_name>
    <description>Oral Administration</description>
    <arm_group_label>Phase 1: Palbociclib 75 mg</arm_group_label>
    <other_name>Ibrance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole 2.5mg</intervention_name>
    <description>Oral Adminstration</description>
    <arm_group_label>Phase 1: Palbociclib 100 mg</arm_group_label>
    <arm_group_label>Phase 1: Palbociclib 125 mg</arm_group_label>
    <arm_group_label>Phase 1: Palbociclib 75 mg</arm_group_label>
    <arm_group_label>Phase 2: RP2D</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T-DM1</intervention_name>
    <description>Intravenous Administration</description>
    <arm_group_label>Phase 1: Palbociclib 100 mg</arm_group_label>
    <arm_group_label>Phase 1: Palbociclib 125 mg</arm_group_label>
    <arm_group_label>Phase 1: Palbociclib 75 mg</arm_group_label>
    <arm_group_label>Phase 2: RP2D</arm_group_label>
    <other_name>Ado-trastuzumab Emtansine</other_name>
    <other_name>Kadcyla</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib 100mg</intervention_name>
    <description>Oral Administration</description>
    <arm_group_label>Phase 1: Palbociclib 100 mg</arm_group_label>
    <other_name>Ibrance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib 125mg</intervention_name>
    <description>Oral Administration</description>
    <arm_group_label>Phase 1: Palbociclib 125 mg</arm_group_label>
    <other_name>Ibrance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Oral Administration</description>
    <arm_group_label>Phase 2: RP2D</arm_group_label>
    <other_name>Ibrance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed diagnosis of Estrogen Receptor (ER) positive and HER2 (human
             epidermal growth factor receptor 2) positive metastatic breast cancer based on local
             laboratory results.

          -  Prior treatment with a taxane (including paclitaxel, docetaxel and/or nanoparticle
             protein-bound paclitaxel).

          -  Prior treatment with trastuzumab with or without pertuzumab.

          -  Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors
             (RECIST) criteria version 1.1.

          -  Eastern Cooperative Oncology Group Performance Status of 0-2

          -  Adequate organ and marrow function

          -  Women must be post-menopausal

          -  Must be able to swallow pills

        Exclusion Criteria:

          -  Current or anticipated use of other investigational agents

          -  Prior therapy with a cyclin-dependent kinase 4/6 inhibitor

          -  Subject has received chemotherapy or radiotherapy within 14 days prior to Cycle 1, Day
             1 of the study or has not recovered from adverse events due to agents administered
             more than 14 days earlier

          -  Subject has leptomeningeal disease

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to palbociclib or other agents used in study

          -  Subject has other illness or disease that the investigator believes will interfere
             with study requirements.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren Nye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KUCC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kerry Hepler</last_name>
    <phone>913-945-7552</phone>
    <email>ctnursenav@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center, West Clinic</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Nurse Navigator</last_name>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center, Westwood Campus</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Nurse Navigator</last_name>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center, Overland Park Clinic</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Nurse Navigator</last_name>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center, North Clinic</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Nurse Navigator</last_name>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center, Lee's Summit Clinic</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Nurse Navigator</last_name>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>palbociclib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Ado-trastuzumab emtansine</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

